CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients with rare diseases manage their conditions. The partnership will allow CSL Behring to make ...

CSL has fleshed out the data from its phase 3 trial of garadacimab, a once-monthly therapy for hereditary angioedema (HAE), preparing regulatory filings and an attempt to wrest market share from ...

ABSECON _ Scores of competitors of all ages will take to the streets, fields and waterways of Absecon this weekend to participate in the 14 th annual Pedal, Paddle, Run- Absecon’s Great Race. The ...